Paclitaxel-coated stent: Feasibility study

ANPI partner BSX updated previously reported 30-day safety data from the double-blind, U.S. TAXUS IV trial in 1,326 patients, showing an overall major adverse cardiac event (MACE) rate of 3% and a st...